Off-label treatments as potential accelerators in the search for the ideal antifungal treatment of cryptococcosis

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Almeida F, Rodrigues ML, Coelho C. The still underestimated problem of fungal diseases worldwide. Front. Microbiol. 10, 214–216 (2019). • The authors suggest the urgent need for more attention to the biology and pathogenesis of fungi worldwide, with special attention to diseases affecting developing countries, as a safeguard for preventing agricultural losses, environmental losses and harm to human health.
  MedlineGoogle Scholar
• 2. Gnat S, Łagowski D, Nowakiewicz A, Dyląg M. A global view on fungal infections in humans and animals: infections caused by dimorphic fungi and dermatophytoses. J. Appl. Microbiol. 131(6), 2688–2704 (2021).
  Medline CASGoogle Scholar
• 3. Borba HHL, Steimbach LM, Riveros BS et al. Cost–effectiveness of amphotericin B formulations in the treatment of systemic fungal infections. Mycoses 61(10), 754–763 (2018).
  MedlineGoogle Scholar
• 4. Wasilczuk K, Korzeniewski K. Immunocompromised travellers. Int. Marit. Health 68(4), 229–237
  MedlineGoogle Scholar
• 5. Segrelles-Calvo G, de S Araújo GR, Frases S. Systemic mycoses: a potential alert for complications in COVID-19 patients. Future Microbiol. 15(14), 1405–1413 (2020).
  CASGoogle Scholar
• 6. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 324(13), 1330–1341 (2020). • This analysis shows the importance of immunosuppression in the treatment of COVID-19 as a perfect scenario for the development of opportunistic mycoses
  MedlineGoogle Scholar
• 7. Sinha P, Matthay MA, Calfee CS. Is a ‘cytokine storm’ relevant to COVID-19? JAMA Intern. Med. 180(9), 1152 (2020).
  Medline CASGoogle Scholar
• 8. Segrelles‐Calvo G, Araújo GRS, Llopis‐Pastor E et al. Prevalence of opportunistic invasive aspergillosis in COVID‐19 patients with severe pneumonia. Mycoses 64(2), 144–151 (2021).
  Medline CASGoogle Scholar
• 9. Idnurm A, Bahn Y-S, Nielsen K, Lin X, Fraser JA, Heitman J. Deciphering the model pathogenic fungus Cryptococcus neoformans. Nat. Rev. Microbiol. 3(10), 753–764 (2005).
  Medline CASGoogle Scholar
• 10. Chayakulkeeree M, Perfect J. Cryptococcosis. Infectious Disease: Diagnosis and Treament of Human Mycoses. © Springer Nature Switzerland AG., 255–276 (2008).
  Google Scholar
• 11. Tsiodras S, Papageorgiou S, Meletiadis J et al. Rhodotorula mucilaginosa associacted meningitis: a subacute entity with high mortality. Case report and review. Med. Mycol. Case Rep. 6, 46–50 (2014).
  MedlineGoogle Scholar
• 12. Reboli AC, Shorr AF, Rotstein C et al. Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome. BMC Infect. Dis. 11(1), 261 (2011).
  Medline CASGoogle Scholar
• 13. Rajasingham R, Smith RM, Park BJ et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect. Dis. 17(8), 873–881 (2017).
  MedlineGoogle Scholar
• 14. Idnurm A, Bahn Y-S, Nielsen K, Lin X, Fraser JA, Heitman J. Deciphering the model pathogenic fungus Cryptococcus neoformans. Nat. Rev. Microbiol. 3(10), 753–764 (2005).
  Medline CASGoogle Scholar
• 15. Krysan DJ. Toward improved anti-cryptococcal drugs: novel molecules and repurposed drugs. Fungal Genet. Biol. 78, 93–98 (2015). •• The article presents the features of an ideal anticryptococcal agent and review current advance for identifying both novel and repurposed drugs as potential new therapies.
  Medline CASGoogle Scholar
• 16. Micallef C, Aliyu SH, Santos R, Brown NM, Rosembert D, Enoch DA. Introduction of an antifungal stewardship programme targeting high-cost antifungals at a tertiary hospital in Cambridge, England. J. Antimicrob. Chemother. 70(6), 1908–1911 (2015).
  Medline CASGoogle Scholar
• 17. Sloan DJ, Dedicoat MJ, Lalloo DG. Treatment of cryptococcal meningitis in resource limited settings. Curr. Opin. Infect. Dis. 22(5), 455–463 (2009).
  MedlineGoogle Scholar
• 18. Chang Y-L, Yu S-J, Heitman J, Wellington M, Chen Y-L. New facets of antifungal therapy. Virulence 8(2), 222–236 (2017). • The authors show an analysis performed to guide optimal treatment of cryptococcal meningitis within resource constraints.
  Medline CASGoogle Scholar
• 19. World Health Organization. Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children: supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva, Switzerland (2018). •• Official guide for managing cryptococcal disease.
  Google Scholar
• 20. Oprea TI, Mestres J. Drug repurposing: far beyond new targets for old drugs. AAPS J. 14(4), 759–763 (2012).
  Medline CASGoogle Scholar
• 21. Ribeiro NQ, Santos APN, Emídio ECP et al. Pioglitazone as an adjuvant of amphotericin B for the treatment of cryptococcosis. Int. J. Antimicrob. Agents 54(3), 301–308 (2019).
  Medline CASGoogle Scholar
• 22. Ribeiro N de Q, Costa MC, Magalhães TFF et al. Atorvastatin as a promising anticryptococcal agent. Int. J. Antimicrob. Agents 49(6), 695–702 (2017).
  Medline CASGoogle Scholar
• 23. Zhai B, Wu C, Wang L, Sachs MS, Lin X. The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections. Antimicrob. Agents Chemother. 56(7), 3758–3766 (2012).
  Medline CASGoogle Scholar
• 24. Delattin N, de brucker K, Vandamme K et al. Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida albicans biofilms. J. Antimicrob. Chemother. 69(4), 1035–1044 (2014).
  Medline CASGoogle Scholar
• 25. Butts A, Krysan DJ. Antifungal drug discovery: something old and something new. PLoS Pathog. 8(9), e1002870 (2012).
  Medline CASGoogle Scholar
• 26. Ogundeji AO, Pohl CH, Sebolai OM. Repurposing of aspirin and ibuprofen as candidate anti-Cryptococcus drugs. Antimicrob. Agents Chemother. 60(8), 4799–4808 (2016).
  Medline CASGoogle Scholar
• 27. Ribeiro N de Q, Costa MC, Magalhães TFF et al. Atorvastatin as a promising anticryptococcal agent. Int. J. Antimicrob. Agents 49(6), 695–702 (2017).
  Medline CASGoogle Scholar
• 28. Fuchs BB, RajaMuthiah R, Souza ACR et al. Inhibition of bacterial and fungal pathogens by the orphaned drug auranofin. Future Med. Chem. 8(2), 117–132 (2016).
  Medline CASGoogle Scholar
• 29. Oliveira EAM, Ferreira GF, Lang KL. Drug repositioning of benzimidazole anthelmintics in the treatment of cryptococcosis: a review. Med. Chem. Res. 31(1), 26–39 (2022).
  CASGoogle Scholar
• 30. Joffe LS, Schneider R, Lopes W et al. The anti-helminthic compound mebendazole has multiple antifungal effects against Cryptococcus neoformans. Front. Microbiol. 8, 535 (2017).
  MedlineGoogle Scholar
• 31. Magalhães TFF, Costa MC, Holanda RA et al. N-acetylcysteine reduces amphotericin B deoxycholate nephrotoxicity and improves the outcome of murine cryptococcosis. Med. Mycol. 58(6), 835–844 (2020).
  Medline CASGoogle Scholar
• 32. Ogundeji AO, Pohl CH, Sebolai OM. The repurposing of anti-psychotic drugs, quetiapine and olanzapine, as anti-Cryptococcus drugs. Front. Microbiol. 8, 815–826 (2017).
  MedlineGoogle Scholar
• 33. Brilhante RSN, Caetano EP, de Oliveira JS et al. Simvastatin inhibits planktonic cells and biofilms of Candida and Cryptococcus species. Braz. J. Infect. Dis. 19(5), 459–465 (2015).
  MedlineGoogle Scholar
• 34. Hai TP, Van AD, Ngan NTT et al. The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans. Mycoses 62(9), 818–825 (2019).
  Medline CASGoogle Scholar
• 35. Ko H-T, Hsu L-H, Yang S-Y, Chen Y-L. Repurposing the thrombopoietin receptor agonist eltrombopag as an anticryptococcal agent. Med. Mycol. 58(4), 493–504 (2019).
  Google Scholar
• 36. Butts A, Koselny K, Chabrier-Roselló Y et al. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo. mBio 5(1), e00765–13 (2014).
  MedlineGoogle Scholar
• 37. Rollini MMM. Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs. Appl. Microbiol. Biotechnol. 58(5), 555–564 (2002).
  MedlineGoogle Scholar
• 38. Hilal-DandanR, KnollmannB, BruntonL. Goodman and Gilman's the Pharmacological Basis of Therapeutics (13th Edition). McGraw Hill, NY, USA (2017).
  Google Scholar
• 39. Manzoni M, Rollini M. Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs. Appl. Microbiol. Biotechnol. 58(5), 555–564 (2002).
  Medline CASGoogle Scholar
• 40. Jia M, Huang W, Li L, Xu Z, Wu L. Statins reduce mortality after non-severe but not after severe pneumonia: a systematic review and meta-analysis. J. Pharm. Pharm. Sci. 18(3), 286–302 (2015).
  MedlineGoogle Scholar
• 41. Thomsen RW, Riis A, Kornum JB, Christensen S, Johnsen SP, Sørensen HT. Preadmission use of statins and outcomes after hospitalization with pneumonia population-based cohort study of 29,900 patients. Arch. Intern. Med. 168(19), 2081–2087 (2008).
  MedlineGoogle Scholar
• 42. Cruz MC, Bartlett MS, Edlind TD. In vitro susceptibility of the opportunistic fungus Cryptococcus neoformans to anthelmintic benzimidazoles. Antimicrob. Agents Chemother. 38(2), 378–380 (1994).
  Medline CASGoogle Scholar
• 43. Bai RY, Staedtke V, Wanjiku T et al. Brain penetration and efficacy of different mebendazole polymorphs in a mouse brain tumor model. Clin. Cancer Res. 21(15), 3462–3470 (2015).
  Medline CASGoogle Scholar
• 44. Cruz MC, Edlind T. β-Tubulin genes and the basis for benzimidazole sensitivity of the opportunistic fungus Cryptococcus neoformans. Microbiology (NY) 143(6), 2003–2008 (1997).
  Medline CASGoogle Scholar
• 45. Palacio JR, Markert UR, Martínez P. Anti-inflammatory properties of N-acetylcysteine on lipopolysaccharide-activated macrophages. Inflamm. Res. 60(7), 695–704 (2011).
  Medline CASGoogle Scholar
• 46. Uraz S, Tahan G, Aytekin H, Tahan V. N-acetylcysteine expresses powerful anti-inflammatory and antioxidant activities resulting in complete improvement of acetic acid-induced colitis in rats. Scand. J. Clin. Lab. Invest. 73(1), 61–66 (2013).
  Medline CASGoogle Scholar
• 47. Jones AL. Mechanism of action and value of N-acetylcysteine in the treatment of early and late acetaminophen poisoning: a critical review. J. Toxicol. Clin. Toxicol. 36(4), 277–285 (1998).
  Medline CASGoogle Scholar
• 48. Bachert C, Hörmann K, Mösges R et al. An update on the diagnosis and treatment of sinusitis and nasal polyposis. Allergy 58(3), 176–191 (2003).
  Medline CASGoogle Scholar
• 49. Casadevall A, Coelho C, Cordero RJB et al. The capsule of Cryptococcus neoformans. Virulence 10(1), 822–831 (2019).
  Medline CASGoogle Scholar
• 50. Laniado-Laborín R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Rev. Iberoam. Micol. 26(4), 223–227 (2009).
  MedlineGoogle Scholar
• 51. Aberg-Wistedt A. The antidepressant effects of 5-HT uptake inhibitors. Br. J. Psychiatry 155(Suppl. 8), 32–40 (1989).
  Google Scholar
• 52. Young TJ, Oliver GP, Pryde D, Perros M, Parkinson T. Antifungal activity of selective serotonin reuptake inhibitors attributed to non-specific cytotoxicity. J. Antimicrob. Chemother. 51(4), 1045–1047 (2003).
  Medline CASGoogle Scholar
• 53. Rainey MM, Korostyshevsky D, Lee S, Perlstein EO. The antidepressant sertraline targets intracellular vesiculogenic membranes in yeast. Genetics 185(4), 1221–1233 (2010).
  Medline CASGoogle Scholar
• 54. Spitzer M, Griffiths E, Blakely KM et al. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol. Syst. Biol. 7(499), 1–14 (2011).
  Google Scholar
• 55. Nayak R, Xu J. Effects of sertraline hydrochloride and fluconazole combinations on Cryptococcus neoformans and Cryptococcus gattii. Mycology 1(2), 99–105 (2010).
  CASGoogle Scholar
• 56. Katende A, Mbwanji G, Faini D et al. Short-course amphotericin B in addition to sertraline and fluconazole for treatment of HIV-associated cryptococcal meningitis in rural Tanzania. Mycoses 62(12), 1127–1132 (2019).
  Medline CASGoogle Scholar
• 57. Villanueva-Lozano H, Treviño-Rangel R de J, González GM et al. Clinical evaluation of the antifungal effect of sertraline in the treatment of cryptococcal meningitis in HIV patients: a single Mexican center experience. Infection 46(1), 25–30 (2018).
  Medline CASGoogle Scholar
• 58. Rhein J, Huppler Hullsiek K, Tugume L et al. Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial. Lancet Infect. Dis. 19(8), 843–851 (2019).
  Medline CASGoogle Scholar
• 59. Dolan K, Montgomery S, Buchheit B, DiDone L et al. Antifungal activity of tamoxifen: in vitro and in vivo activities and mechanistic characterization. Antimicrob. Agents Chemother. 53(8), 3337–3346 (2009).
  Medline CASGoogle Scholar
• 60. Cheng G. Eltrombopag, a thrombopoietin-receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile. Ther. Adv. Hematol. 3(3), 155–164 (2012).
  Medline CASGoogle Scholar
• 61. Dihazi H, Kessler R, Eschrich K. High osmolarity glycerol (HOG) pathway-induced phosphorylation and activation of 6-phosphofructo-2-kinase are essential for glycerol accumulation and yeast cell proliferation under hyperosmotic stress. J. Biol. Chem. 279(23), 23961–23968 (2004).
  Medline CASGoogle Scholar
• 62. Silva-Abreu M, Espinoza L, Rodríguez-Lagunas M et al. Human skin permeation studies with PPARγ agonist to improve its permeability and efficacy in inflammatory processes. Int. J. Mol. Sci. 18(12), 2548 (2017).
  MedlineGoogle Scholar
• 63. Serghides L, McDonald CR, Lu Z et al. PPARγ agonists improve survival and neurocognitive outcomes in experimental cerebral malaria and induce neuroprotective pathways in human malaria. PLoS Pathog. 10(3), e1003980 (2014).
  MedlineGoogle Scholar
• 64. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol. 2(10), 748–759 (2002).
  Medline CASGoogle Scholar
• 65. Schlottfeldt S, Fernandes M, Martins M, Fonseca D et al. Prevention of amphotericin B nephrotoxicity through use of phytotherapeutic medication. Rev. Esc. Enferm. USP doi:10.1590/S0080-623420150000700011 (2015).
  MedlineGoogle Scholar
• 66. Gardner DM. Modern antipsychotic drugs: a critical overview. Can. Med. Assoc. J. 172(13), 1703–1711 (2005).
  MedlineGoogle Scholar
• 67. Suarez-Almazor ME, Spooner CH, Belseck E, Shea B. Auranofin versus placebo in rheumatoid arthritis. Cochrane Database Syst. Rev. 1(2), CD002048–CD002077 (2000).
  Google Scholar